Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Tag Archive for: Product rights
Regeneron Pharmaceuticals Inc. said on Thursday the company would buy the global rights to the cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.